In Aug. 2021, immuno-oncology company, Trillium Therapeutics, was acquired by Pfizer for $2.3 billion, adding Trillium’s two CD47-targeting biologics, TTI-621 and TTI-622, to Pfizer’s oncology pipeline. The acquisition followed Gilead’s $4.9B buyout of Forty Seven in early 2020, after clinical data was presented on Forty Seven’s lead, the anti-CD47 monoclonal Read more…
The September edition of Small Molecules of the Month, features a number of fascinating molecules and mechanisms, including a beta-lactamase inhibitor optimized to have single agent antibiotic activity, a biased agonist of S1P1 that minimizes receptor internalization in favor of GCPR agonism, an oral AR degrader similar to ARV-110 and Read more…
Antibody-drug conjugates (ADCs) have gone through several waves of enthusiasm since being first tested in animal models in the 1960’s. The first clinical trials with ADCs were conducted in the 1980’s, and an ADC was first approved in 2000 (Mylotarg, see below). Mylotarg, however, was famously withdrawn from the market Read more…
Recently our non-profit partner, California Life Sciences, completed nominations for the 2021 Pantheon Award for Scientific Advancement. We’re glad to see several drug hunters and drug discovery companies across the award categories, and we hope you’ll help get some industry drug hunters deserved recognition for their achievements by voting here! Read more…
The August edition of Small Molecules of the Month, features a recently approved, dibasic oral kallikrein inhibitor, a spirocyclobutene-containing FXR agonist, a NaV1.6 clinical candidate, a remarkably long acting RIPK2 PROTAC, and several other interesting clinical candidates. Thanks to reviewers Joachim Rudolph, Kim Huard, Jake Schwarz, Julien Lefranc, and Chris Read more…
By Christian Kuttruff and Julien Lefranc The first disclosures of new drug candidates are always the highlight of medicinal chemistry conferences. Six novel drug candidates were recently disclosed by European companies at the European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry (EFMC-ISMC) Conference in Basel, including a KRAS Read more…